TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06270316: Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease

Sponsor: UniQure Biopharma B.V. · Phase: PHASE1/PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 20 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,926,100

Rescue Site Savings

+$1,269,475

Unlock Full NCT06270316 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06270316 Rescue Dossier →